Kevin Kalinsky, MD, MS, from the Winship Cancer Institute in Atlanta, GA, highlights the clinical significance of serum anti-Müllerian hormone (AMH) testing. This readily available test serves as a valuable tool in determining menopausal status, particularly in cases where it may be ambiguous, such as in patients who have undergone hysterectomy but still have their ovaries. Dr Kalinsky emphasizes the importance of understanding the lower limit of detection for AMH tests, as variations in this limit can impact clinical interpretation. He notes that around 50% of patients over age 50 had a low AMH level, contrasting with only about 3% in the age 45 category. This discussion underscores the importance of utilizing available tests judiciously and being aware of their limitations for accurate clinical decision-making. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
